Mismatch Repair Status and Lymph Node Ratio in Survival Prediction of Stage <scp>II</scp>/<scp>III</scp> Rectal Cancer Patients: A Comprehensive Analysis of a Multi‐Center Retrospective Study

Kailong Zhao, Wenwen Pang, Xinyu Liu, Kemin Ni, Weifeng Gao, Zhiquan Tan, Jun Xue, Weizheng Liang, Xueliang Wu, Xipeng Zhang, Xiaomin Su, Chunze ZhangCancer 2025 · DOI

TL;DR

This study reveals that combining microsatellite instability (MSI) status with lymph node ratio (LNR) offers a more precise way to predict survival in Stage II/III rectal cancer patients. Crucially, it suggests that patients with deficient mismatch repair (dMMR) status may not benefit from adjuvant chemotherapy and could even experience worse outcomes with it.

What Problem Does This Paper Address?

Colorectal cancer remains a significant global health challenge. Accurately predicting patient prognosis and tailoring treatment is vital for improving outcomes. While microsatellite instability (MSI) status, particularly dMMR (deficiency in mismatch repair proteins), has been linked to prognosis, and lymph node ratio (LNR) is a known predictor of survival, their combined impact and interaction with adjuvant chemotherapy (ACT) in Stage II/III rectal cancer patients haven't been fully elucidated. Specifically, the debate continues on whether dMMR patients benefit from ACT, as some studies suggest they have a better prognosis and may not need it, while others show mixed results. This paper aims to clarify these relationships to provide better clinical guidance.

Methods

This retrospective, multi-center study analyzed data from 1104 patients with Stage II/III rectal cancer who underwent radical resection and had MMR status assessed. Key methods included:

  • MMR Status Determination: Immunohistochemistry (IHC) was used to assess the expression of mismatch repair proteins (MLH1, PMS2, MSH6, and MSH2). dMMR was defined by the deficiency of one or more of these proteins, while pMMR indicated proficient repair.
  • Lymph Node Ratio (LNR) Calculation: LNR was calculated as the ratio of positive lymph nodes (PLN) to the total number of examined lymph nodes (ELN).
  • Statistical Analysis:
    • X-tile software: Used to determine optimal cutoff values for LNR.
  • Kaplan-Meier curves and Log-rank tests: Employed to assess survival differences between groups.
  • Cox multivariate regression analysis: Used to identify independent prognostic factors for overall survival (OS) and disease-free survival (DFS).
  • Stratified analysis: Performed to examine the impact of ACT and MMR status within specific LNR ranges.

Datasets

The study utilized a dataset of 1104 patients diagnosed with rectal cancer at three major medical centers in China between 2012 and 2019. This dataset included patient demographics, pathological information (T stage, N stage, TNM stage, tumor differentiation, MMR status, etc.), and postoperative treatment details (ACT).

Key Insights and Ideas

  • Synergistic Prognostic Power: The combination of LNR and MMR status provides a more nuanced and accurate prediction of prognosis than either factor alone, especially within specific LNR ranges.
  • ACT's Detrimental Effect on dMMR: The most striking finding is that adjuvant chemotherapy appears to negatively impact the prognosis of dMMR patients, a stark contrast to its potential benefit in pMMR patients. This challenges the standard approach of offering ACT to all patients in these stages.
  • LNR as a Critical Stratifier: The LNR value acts as a crucial stratifier, revealing that the prognostic significance of MMR status is most apparent within a specific LNR range (0.03-0.31).
  • No Benefit for dMMR Patients from ACT: The study strongly suggests that dMMR patients with Stage II/III rectal cancer do not benefit from postoperative adjuvant chemotherapy and may even fare worse.

Key Results

  • Prevalence of dMMR: Approximately 6.47% of Stage II and III colorectal cancer patients in this cohort were found to have dMMR status.
  • LNR and Survival: Significant differences in OS and DFS were observed between dMMR and pMMR patients when the LNR ranged from 0.03 to 0.31. In this range, pMMR patients showed a better prognosis.
  • ACT Impact on dMMR: Stratified analysis revealed that postoperative chemotherapy did not affect the prognosis within the dMMR patient group. In fact, when ACT was administered to dMMR patients, their prognosis was significantly worse compared to pMMR patients receiving ACT.
  • ACT Benefit for pMMR: Conversely, pMMR patients who received postoperative chemotherapy showed a better prognosis compared to those who did not, although this difference was not always statistically significant.
  • Multivariate Analysis: Age, T stage, Grade, LNR, and PNI were identified as independent risk factors for OS. Age, T stage, Grade, and PNI were independent risk factors for DFS. ACT was identified as a favorable factor for DFS.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: Inherent recall bias and potential for unmeasured confounding factors.
  • Exclusion of Half the Cohort: Nearly half of the initial study population was excluded due to unavailable MMR status, potentially reducing the credibility of the results.
  • Need for Larger Studies: The study calls for larger, more comprehensive prospective studies to confirm these findings.
  • Optimal LNR Cutoff: While the study identified useful LNR cutoffs (0, 0.03, 0.31), the optimal cutoff for LNR in rectal cancer remains a subject of ongoing research, with variations reported in the literature.
  • Personalized Treatment: Future research should integrate molecular markers and target specific patient populations to refine LNR's prognostic value and enable more personalized treatment plans.

The study's findings provide a strong foundation for re-evaluating adjuvant chemotherapy strategies for dMMR rectal cancer patients and highlight the importance of integrating LNR into prognostic assessments.

Summary updated

Abstract

Integrating LNR based on the microsatellite status of colorectal tumors provides comprehensive prognostic predictions, enhancing postoperative prognostic considerations for tumor patients. Additionally, our study suggests that patients with stage II and III colorectal cancer with dMMR status do not require any adjuvant chemotherapy postoperatively.
BibTeX
@inproceedings{zhao2025mismatch,
  author = {Kailong Zhao and Wenwen Pang and Xinyu Liu and Kemin Ni and Weifeng Gao and Zhiquan Tan and Jun Xue and Weizheng Liang and Xueliang Wu and Xipeng Zhang and Xiaomin Su and Chunze Zhang},
  title = {{Mismatch Repair Status and Lymph Node Ratio in Survival Prediction of Stage <scp>II</scp>/<scp>III</scp> Rectal Cancer Patients: A Comprehensive Analysis of a Multi‐Center Retrospective Study}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1002/cam4.70756},
}
Figure